Friday, November 17, 2017 6:56:39 PM
I completely agree with your "lack of diligence" assertion.
My primary concerns about DECN, at this point, are the effectiveness of its marketing and its distribution channels. And I consider metrics about these critical. Down the road, profit and accurate reporting metrics will become imperatives.
I suspect our opinions, for the long term (if there is one), aren't that far apart. For the here and now, we appear to disagree on priorities.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM